HK Stock Market Move | XUNCE(03317) rose by more than 11% in early trading. TokenOS restructures its commercial system, opening up growth potential.
Xunze (03317) rose more than 11% in early trading, up 11.05% as of the time of publication, to HK$105, with a turnover of HK$170 million.
XUNCE (03317) rose more than 11% in early trading, rising 11.05% to 105 Hong Kong dollars as of the time of writing, with a trading volume of 170 million Hong Kong dollars.
In terms of news, XUNCE recently announced a financing of 2.35 billion Hong Kong dollars, under the escort of many top international investment banks such as Morgan Stanley and Goldman Sachs. This fundraising is seen as an "accelerator" for the company in the key stage of AI landing and validation, injecting sufficient funds for the company to accelerate the landing and validation of AI as well as industry expansion.
Huatai released a research report stating that XUNCE, as a leading domestic scene token similar to Palantir, has built a high technical and customer barrier relying on the asset management track, continuously promoting the replication and landing of scenarios across the industry, and upgrading the business model to charge based on tokens through TokenOS, driving revenue growth. We are optimistic about the company's continuous high growth in performance based on hardcore real-time data technology, cross-industry expansion dividends, and a business model based on Token billing, opening up mid- to long-term growth and valuation ceilings.
Related Articles

JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
.png)
RECOMMEND





